These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Frey SE; Bernstein DI; Brady RC; Keitel WA; El Sahly H; Rouphael NG; Mulligan MJ; Atmar RL; Edupuganti S; Patel SM; Dickey M; Graham I; Anderson EL; Noah DL; Hill H; Wolff M; Belshe RB Vaccine; 2015 Jan; 33(1):163-73. PubMed ID: 25444805 [TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial. Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK; Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411 [TBL] [Abstract][Full Text] [Related]
6. Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost. Ledgerwood JE; Hu Z; Costner P; Yamshchikov G; Enama ME; Plummer S; Hendel CS; Holman L; Larkin B; Gordon I; Bailer RT; Poretz DM; Sarwar U; Kabadi A; Koup R; Mascola JR; Graham BS; Contemp Clin Trials; 2015 Sep; 44():112-118. PubMed ID: 26275339 [TBL] [Abstract][Full Text] [Related]
7. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial. Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea. Choi WS; Noh JY; Lee J; Choi JY; Lee JS; Kim MS; Kim HS; Bang J; Lavis N; Kim WJ Hum Vaccin Immunother; 2018 Mar; 14(3):587-592. PubMed ID: 28933625 [TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age. DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience. Nicolay U; Heijnen E; Nacci P; Patriarca PA; Leav B Int J Infect Dis; 2019 Aug; 85S():S1-S9. PubMed ID: 30926542 [TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial. Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study. Hu Y; Chu K; Lavis N; Li X; Liang B; Liu S; Shao M; Shu JD; Tabar C; Samson S Hum Vaccin Immunother; 2019; 15(5):1066-1069. PubMed ID: 30779689 [TBL] [Abstract][Full Text] [Related]
13. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial. Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857 [TBL] [Abstract][Full Text] [Related]
14. Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine. Shinde V; Cai R; Plested J; Cho I; Fiske J; Pham X; Zhu M; Cloney-Clark S; Wang N; Zhou H; Zhou B; Patel N; Massare MJ; Fix A; Spindler M; Thomas DN; Smith G; Fries L; Glenn GM Clin Infect Dis; 2021 Dec; 73(11):e4278-e4287. PubMed ID: 33146720 [TBL] [Abstract][Full Text] [Related]
15. Phase 1 study of pandemic H1 DNA vaccine in healthy adults. Crank MC; Gordon IJ; Yamshchikov GV; Sitar S; Hu Z; Enama ME; Holman LA; Bailer RT; Pearce MB; Koup RA; Mascola JR; Nabel GJ; Tumpey TM; Schwartz RM; Graham BS; Ledgerwood JE; PLoS One; 2015; 10(4):e0123969. PubMed ID: 25884189 [TBL] [Abstract][Full Text] [Related]
16. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial. Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. DiazGranados CA; Dunning AJ; Kimmel M; Kirby D; Treanor J; Collins A; Pollak R; Christoff J; Earl J; Landolfi V; Martin E; Gurunathan S; Nathan R; Greenberg DP; Tornieporth NG; Decker MD; Talbot HK N Engl J Med; 2014 Aug; 371(7):635-45. PubMed ID: 25119609 [TBL] [Abstract][Full Text] [Related]
18. MF59-adjuvanted seasonal trivalent inactivated influenza vaccine: Safety and immunogenicity in young children at risk of influenza complications. Patel SS; Bizjajeva S; Heijnen E; Oberye J Int J Infect Dis; 2019 Aug; 85S():S18-S25. PubMed ID: 31051279 [TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults. Stevanovic G; Lavadinovic L; Filipovic Vignjevic S; Holt R; Ilic K; Berlanda Scorza F; Sparrow E; Stoiljkovic V; Torelli G; Madenwald T; Socquet M; Barac A; Ilieva-Borisova Y; Pelemis M; Flores J Hum Vaccin Immunother; 2018 Mar; 14(3):579-586. PubMed ID: 29239682 [TBL] [Abstract][Full Text] [Related]